Dynavax Technologies Corporation (DVAX) Stock Rating Upgraded by ValuEngine

Dynavax Technologies Corporation (NASDAQ:DVAX) was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Thursday, September 7th.

Several other research analysts have also recently weighed in on the stock. Royal Bank Of Canada reissued a “buy” rating and set a $26.00 price objective on shares of Dynavax Technologies Corporation in a report on Friday, September 1st. Cowen and Company reissued an “outperform” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a report on Thursday, August 10th. William Blair reissued an “outperform” rating and set a $30.00 price objective on shares of Dynavax Technologies Corporation in a report on Wednesday, August 9th. Zacks Investment Research upgraded shares of Dynavax Technologies Corporation from a “sell” rating to a “hold” rating in a research report on Friday, August 4th. Finally, BidaskClub lowered shares of Dynavax Technologies Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $24.67.

Dynavax Technologies Corporation (NASDAQ:DVAX) opened at 20.80 on Thursday. The firm’s market cap is $1.14 billion. Dynavax Technologies Corporation has a 1-year low of $3.20 and a 1-year high of $21.85. The stock has a 50 day moving average price of $17.37 and a 200-day moving average price of $9.52.

Dynavax Technologies Corporation (NASDAQ:DVAX) last issued its earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.09. Dynavax Technologies Corporation had a negative net margin of 1,323.99% and a negative return on equity of 92.09%. The business had revenue of $0.11 million during the quarter, compared to analysts’ expectations of $0.15 million. During the same period in the previous year, the company earned ($0.75) earnings per share. Equities research analysts forecast that Dynavax Technologies Corporation will post ($1.58) EPS for the current year.

TRADEMARK VIOLATION NOTICE: “Dynavax Technologies Corporation (DVAX) Stock Rating Upgraded by ValuEngine” was originally published by BBNS and is the property of of BBNS. If you are viewing this story on another publication, it was copied illegally and republished in violation of US & international trademark and copyright legislation. The original version of this story can be viewed at https://baseballnewssource.com/markets/dynavax-technologies-corporation-dvax-upgraded-to-hold-at-valuengine/1620498.html.

Hedge funds have recently added to or reduced their stakes in the company. Endurant Capital Management LP lifted its holdings in shares of Dynavax Technologies Corporation by 205.4% in the first quarter. Endurant Capital Management LP now owns 173,458 shares of the biopharmaceutical company’s stock worth $1,032,000 after buying an additional 116,658 shares in the last quarter. Highbridge Capital Management LLC purchased a new position in shares of Dynavax Technologies Corporation in the first quarter worth $513,000. KCG Holdings Inc. purchased a new position in shares of Dynavax Technologies Corporation in the first quarter worth $402,000. Teachers Advisors LLC lifted its holdings in shares of Dynavax Technologies Corporation by 9.1% in the fourth quarter. Teachers Advisors LLC now owns 67,640 shares of the biopharmaceutical company’s stock worth $267,000 after buying an additional 5,618 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Dynavax Technologies Corporation by 14.4% in the first quarter. Vanguard Group Inc. now owns 1,825,662 shares of the biopharmaceutical company’s stock worth $10,864,000 after buying an additional 230,373 shares in the last quarter. 60.20% of the stock is currently owned by hedge funds and other institutional investors.

About Dynavax Technologies Corporation

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dynavax Technologies Corporation (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Waiting But Magic Number Down to One
Los Angeles Dodgers Waiting But Magic Number Down to One
Young Girl Hit by Foul Ball Rushed to Hospital
Young Girl Hit by Foul Ball Rushed to Hospital
New Home Run Record Reached in Major League Baseball
New Home Run Record Reached in Major League Baseball
Will 2017 MLB Season End with No 20-Game Winner?
Will 2017 MLB Season End with No 20-Game Winner?
Cleveland Indians Winning Streak Snapped at 22
Cleveland Indians Winning Streak Snapped at 22
Tigers Player Might Play All Nine Positions During Same Game
Tigers Player Might Play All Nine Positions During Same Game


Leave a Reply

 
© 2006-2017 BBNS.